You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
Technical Feasibility Demonstrated for Transdermal Delivery of BA058; Study Endpoints of Pharmacokinetic Profile, Safety, and Tolerability Successfully Met; Results Support Plan for Future Phase 2 Proof-of-Concept Clinical Trial
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing CAMBRIDGE, MA--(Marketwire - Dec 16, 2011) - Radius Health, Inc. ("Radius") announced today the closing of the third and final equity tranche of the company's $91 million financing round announced in May
Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy CAMBRIDGE, MA--(Marketwire - Dec 5, 2011) - C. Richard Lyttle retires as President and CEO and will serve as interim CSO Kurt Graves